Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scorpius Holdings Inc SCPX

Healthcare Biotechnology
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio... see more

Recent & Breaking News (NYSEAM:SCPX)

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO

GlobeNewswire January 8, 2024

NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University

GlobeNewswire January 3, 2024

NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University

GlobeNewswire December 21, 2023

NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company

GlobeNewswire December 18, 2023

NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets

GlobeNewswire December 12, 2023

NightHawk Biosciences Provides Q3 2023 Business Update

GlobeNewswire November 20, 2023

NightHawk Biosciences Provides Q2 2023 Business Update

GlobeNewswire August 14, 2023

NightHawk Biosciences Provides Q1 2023 Business Update

GlobeNewswire May 15, 2023

NightHawk Biosciences Provides 2022 Year End Business Update

GlobeNewswire March 31, 2023

NightHawk Biosciences Provides Third Quarter 2022 Business Update

GlobeNewswire November 14, 2022

Nighthawk Biosciences' Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility

GlobeNewswire October 21, 2022

NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory

GlobeNewswire August 23, 2022

NightHawk Biosciences Provides Second Quarter 2022 Business Update

GlobeNewswire August 10, 2022

NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services

GlobeNewswire June 13, 2022

NightHawk Biosciences Provides First Quarter 2022 Business Update

GlobeNewswire May 16, 2022

NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35

GlobeNewswire May 10, 2022

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open Today

GlobeNewswire May 3, 2022

Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

GlobeNewswire April 27, 2022

Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics

GlobeNewswire April 20, 2022

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

GlobeNewswire April 19, 2022